Blue Horseshoe Stocks

DGHG, PROT, ALCL – Stocks Today

Diversified Global Holdings Group, Inc DGHG

DGHG is solid, in fact one of the best companies we have ever had the pleasure of covering. The stock recently moved up an exchange to the OTCBB, and since that time, has appreciated in value more than 40%

DGHG closed at 1.42 on Friday. That’s roughly 100% in total possible gains from its seventy-cent low during the time that we have been interested in the stock.

As if our confidence in the future of this company wasn’t already brimming over, this morning we see the release of some really favorable 3rd Quarter Financials that are almost certain to stir up added outside interest:

Company Reports Third Quarter Revenues of $33.3 Million, Up Substantially Over Prior Year Third Quarter, and Third Quarter Net Earnings of $2 Million

ORLANDO, Fla., Nov 15, 2011 (GlobeNewswire via COMTEX) — Diversified Global Holdings Group Inc. (OTCBB:DGHG) announced today its financial results for the nine months ended September 30, 2011. The Company attributes its improved results over the comparable period in 2010 to a number of successful acquisitions during 2010.

For the nine months ended September 30, 2011, net earnings increased to $2 million from $700,000, an increase of approximately $1.3 million or 185% from the period ended September 30, 2010.

Gross margin was $5.9 million for the nine months ended September 30, 2011, compared to $3.0 million for the same period in 2010, representing an increase of $2.9 million or 97% over the previous year. Gross margin was approximately 17.7% percent for the nine months ended September 30, 2011. The Company estimates that gross margins will steadily improve in 2012 with the scheduled completion of existing work projects and the addition of several more acquisitions contributing to estimated higher margins in line with its business plan.

For the three months ended September 30, 2011 net earnings increased to $1.3 million as compared to $540,746 for the three months ended September 30, 2010 representing an increase of $801,000 or 140% over the previous year. The Company reported revenues for the three months ended September 30, 2011 of $23.3 million compared to $5.3 million for the three months ended September 30, 2010 representing an increase of approximately $18 million or 339% over the previous year.

Proteonomix, Inc. PROT

PROT is another play that we came upon at just the right time. Yesterday’s close at the high-of-day (.72), provided traders with the opportunity to catch an intraday swing of 58% from the low at .455.

From our initial alert at .40, a total gain of 80% would have been possible.

This is one of the better reader-submitted picks we have ever had the wherewithal to follow, and it turned out to be a great decision on our part to do so. Everyone who benefited here owes their thanks to Adam F.- ourselves included. Thanks again Adam, and keep it up!

Atlas Capital Holdings Inc ALCL

We really wanted to announce our new pick this morning, but because of a short delay, that will have to wait a while longer. Instead, we decided to scout out another new one for you anyway, for the ones of you salivating for some “fresh meat” as it were.

ALCL has been trading at a relative bottom in the one-to-two cent range for roughly the past month-and-a-half. Oftentimes, a new PR is enough to kick start a bottom play into action, and we are hoping that is the case with ALCL.

BOCA RATON, FL, Nov 15, 2011 (MARKETWIRE via COMTEX) — Atlas Capital Holdings Inc. (OTCQB: ALCL) (OTCBB: ALCL) (PINKSHEETS: ALCL) (the “Company”) reported today that Textraw, its wholly owned subsidiary, has secured pre-orders from commercial landscapers for its patented Textraw synthetic pine straw.

“It is exciting that Textraw’s previous clients are reaching out to purchase the product as it shows the demand for the patented product line. One truck load of Textraw generates over $35,000 in revenue for the company and so when clients are requesting multi-truckloads, it highlights our investment opportunity at an early stage,” stated Christopher Davies, CEO of Atlas Capital Holdings, Inc.

EXTO – Exit Only, Inc. | PROT – Proteonomix, Inc. | Stocks Today

Exit Only, Inc. EXTO

EXTO saw a stout gain of 17% on Friday. We are going to be monitoring closely in hopes to see the stock break resistance at its 50-day moving average of .0082.

The ultimate goal of course would be to see EXTO attain .01 or better as we saw back in early September.

Proteonomix, Inc. PROT

PROT still has a good-looking chart, with MACD convergence, and a strengthening RSI. What initially began as a passing momentum play has now garnered our further attention, as potential still appears to exist.

As low as .40 at the time of our first mention, the stock closed at .51 on Friday, for a 22% gain. If the ripening chart is any indicator, that appreciation may be only a prelude to even larger gains.

Just a Reminder – New Pick Next Week!

We hope everyone has a pleasant weekend. Here at Blue Horseshoe Stocks, we are already looking forward to next week, as we will be releasing a new pick that has us really excited!

Consider this a reminder to check back with us regularly over the next few trading days.

Stay Safe & Stay Tuned!

-Blue Horseshoe

CSOC, MILV, PROT – Today’s Stocks

Caduceus Software Systems Corp. CSOC

Mistral Ventures, Inc. MILV

We released CSOC as a momentum alert on Nov. 7th. Since that time, we caught a low at .054, meaning today’s high of .09 represents a 66% gain in just four days’ time.

We had previously drawn parallels between CSOC and our last momentum play, MILV, noting that “We are not getting impatient with CSOC, as sometimes it takes several days for many of our plays to develop as in the case of MILV.” -Our Newsletter for Nov.9th

We promise, we don’t have the power to see the future, it just seems that way sometimes!

We first alerted MILV at .055, followed by a dip to .047, subsequently hitting a high of .142. That’s a total possible gain of 202% during a process which took about two weeks. At present, our alert of CSOC is only about four days old, thus the next week and a half will tell the story of how close CSOC can come to MILV’s accomplishment.

Proteonomix, Inc. PROT

We are seldom late to the party, and in the case of PROT, it appears we are a bit early. A reader pick, PROT, has the look of a stock that could rock at any moment. At the moment, things are pretty quiet, but with this technically sound chart, any small amount of buying pressure could kick into motion one heck of a run.

______________________

Proteonomix, Inc. – PROT – Hot Stock Today

Proteonomix, Inc. PROT

One of our readers, Adam F., took our offer of suggesting picks to heart, and called our attention to PROT. After examining the stock, we really like the setup of the chart, so that’s how we decided to begin today’s report.

As recently as August, PROT was trading .85-.95, followed by big sell-off to .32, a bottom which was just reached last Friday. Sitting here at a base, it is an excellent time to consider entry, as the stocks recovery has begun, evidenced in the stocks run to .46 yesterday, a 44% gain from its bottom.

A retesting of this past Summer’s highs would mean added gains on the order of 100% or more.

In a recent press release, the company alluded to its plans to test its stem cell treatments overseas, where the costs and barriers associated with introducing such treatments are far lower. A figurative and literal testing ground before attempting to enter the American market.

MOUNTAINSIDE, NJ, Oct 19, 2011 (MARKETWIRE via COMTEX) — PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it intends to move forward with the testing of its StromaCel technology through its PRTMI subsidiary or its affiliates. The Company decided to examine the possibility of testing its cardiac stem cell treatment offshore in light of the progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease (“ESLD”), in the United States.

Michael Cohen, President of the Company, stated: “Since we progress toward the commencement of our trial of UMK-121 in the United States, we have decided to explore the possible testing of our cardiac treatment offshore in order to reduce the cost of bringing the cardiac treatment to market. This strategic decision is being made in recognition of the increasing costs associated with bringing a new drug to market in the United States through the NDA (New Drug Application) process and the availability of expert medical testing capabilities offshore at a fraction of the cost.”

Thanks again to Adam F. for bringing this bottom-play opportunity to our attention, for more information, please visit:

http://www.proteonomix.com

______________________

ATTENTION READERS!

We will be introducing a brand new play next week, so don’t forget to pay close attention! We are really excited about what we think this stock can do in the next few weeks!